Membranoproliferative Glomerulonephritis Associated with Nivolumab Therapy

Nivolumab is an immune checkpoint inhibitor that targets programmed death-1 on T cells and is designed to amplify an immunologic reaction against cancer cells. However, upregulation of the immune system with checkpoint inhibition is nonspecific, and it can be associated with certain renal side effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Cruz-Whitley, Jessica, Giehl, Nolan, Jen, Kuang-Yu, Young, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060432/
https://www.ncbi.nlm.nih.gov/pubmed/32257470
http://dx.doi.org/10.1155/2020/2638283

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060432/
https://www.ncbi.nlm.nih.gov/pubmed/32257470
http://dx.doi.org/10.1155/2020/2638283

Ejemplares similares